CN Stock MarketDetailed Quotes
000627 Hubei Biocause Pharmaceutical
- 4.35
- +0.23+5.58%
Not Open Nov 19 15:00 CST
21.49BMarket Cap-27884P/E (TTM)
4.36High3.96Low2.59MlotVolume4.01Open4.12Pre Close1.09BTurnover5.69%Turnover RatioLossP/E (Static)4.94BShares4.9552wk High0.99P/B19.80BFloat Cap1.6152wk Low4.53Limit Up4.55BShs Float16.97Historical High3.71Limit Down9.71%Amplitude0.45Historical Low--Dividend TTM4.19Avg Price1.10MlotAsk--Div YieldTTM100Lot Size1.40MlotBid
Hubei Biocause Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Refunds of taxes and levies | ---- | ---- | --3.04M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Premiums received from original insurance contracts | -9.78%30.77B | -15.12%24.23B | -21.53%15.15B | 6.46%39.64B | 20.66%34.11B | 33.79%28.54B | 27.32%19.31B | -1.76%37.23B | 4.93%28.27B | 22.82%21.33B |
| Net cash received from reinsurance business | ---- | ---- | ---8.64M | -99.86%2.69M | -30.50%15.38M | ---- | ---- | --1.89B | --22.13M | ---- |
| Net increase in deposits from policyholders | -453.99%-18.65B | -427.03%-17.94B | -511.97%-15.92B | -177.02%-3.04B | 471.37%5.27B | 10,249.20%5.49B | 18,841.41%3.86B | 16.83%3.94B | -60.35%921.86M | -91.59%53M |
| Cash received relating to other operating activities | -41.33%1.01B | 8.98%786.33M | 25.14%462.26M | 5.52%2.12B | 90.34%1.72B | 21.17%721.51M | -18.68%369.4M | -3.02%2.01B | 19.39%903.55M | 7.10%595.44M |
| Cash inflows from operating activities | -68.05%13.13B | -79.64%7.07B | -101.33%-312.08M | -14.10%38.72B | 36.51%41.11B | 58.08%34.75B | 50.41%23.55B | 3.99%45.08B | 0.31%30.11B | 18.46%21.98B |
| Staff behalf paid | -8.45%512.54M | -6.71%366.26M | 0.05%170.86M | -0.72%705.8M | -0.75%559.83M | -0.43%392.59M | -13.51%170.78M | 2.35%710.91M | 5.89%564.08M | 2.06%394.27M |
| All taxes paid | -9.33%305.36M | -21.86%226.9M | -46.33%101.41M | 33.97%403.02M | 25.81%336.79M | 42.55%290.37M | 51.34%188.96M | -51.00%300.83M | 21.02%267.7M | 19.95%203.7M |
| Cash paid for fees and commissions | -61.54%1.42B | -63.10%1.14B | -63.88%741.58M | 9.94%3.83B | 22.24%3.7B | 29.29%3.1B | 20.09%2.05B | -1.49%3.48B | 7.87%3.03B | 2.96%2.4B |
| Cash paid for indemnity of original insurance contract | 2,000.31%20.35B | 51.86%22.83B | 4,148.61%16.45B | 50.73%2.35B | -20.46%968.94M | -35.73%15.03B | -14.02%387.27M | 24.26%1.56B | -95.56%1.22B | 5.07%23.39B |
| Net cash for reinsurance | --3.01B | 31.33%8.36M | ---- | ---- | ---- | 143.46%6.37M | --14.37M | ---- | ---- | -508.42%-14.65M |
| Policy dividend cash paid | -22.25%21.3M | -20.67%16.6M | -2.62%11.14M | -41.07%33.82M | -44.12%27.39M | -42.02%20.92M | -45.86%11.44M | 42.73%57.38M | 63.87%49.02M | 67.66%36.09M |
| Cash paid relating to other operating activities | -71.28%5.78B | -29.00%566.67M | -80.65%2.27B | -30.45%21.87B | -22.09%20.13B | 40.24%798.1M | -32.21%11.75B | -4.67%31.45B | 2,058.34%25.84B | -5.05%569.11M |
| Cash outflows from operating activities | 22.09%31.41B | 28.07%25.15B | 35.54%19.75B | -22.28%29.19B | -16.93%25.72B | -27.19%19.64B | -26.52%14.57B | -4.14%37.56B | -3.90%30.97B | 4.68%26.98B |
| Net cash flows from operating activities | -218.78%-18.27B | -219.68%-18.08B | -323.60%-20.06B | 26.71%9.53B | 1,904.99%15.38B | 402.46%15.11B | 314.78%8.97B | 80.32%7.52B | 61.32%-852.27M | 30.78%-4.99B |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | -23.49%83.94B | -13.02%59.34B | 36.40%39.98B | 102.06%154.69B | 75.53%109.71B | 65.69%68.22B | -2.02%29.31B | -10.48%76.56B | 1.30%62.5B | 26.50%41.17B |
| Cash received from returns on investments | 63.60%4.96B | 32.37%3.51B | 19.70%1.59B | -49.35%3.83B | -43.43%3.03B | -26.75%2.65B | -26.43%1.33B | -17.69%7.57B | -18.85%5.36B | -21.12%3.61B |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | -52.89%563.61K | -57.73%482.03K | 239.11%62.6K | 652.27%1.62M | 498.16%1.2M | 817.13%1.14M | -61.76%18.46K | -87.93%215.53K | -91.64%200K | -45.57%124.35K |
| Net cash received from disposal of subsidiaries and other business units | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --16.96M | ---- | ---- |
| Cash received relating to other investing activities | ---- | ---- | ---- | --329.73K | ---- | ---- | ---- | ---- | --3.03M | --3.03M |
| Cash inflows from investing activities | -21.15%88.91B | -11.33%62.84B | 35.67%41.58B | 88.40%158.53B | 66.12%112.75B | 58.22%70.87B | -3.42%30.65B | -11.17%84.14B | -0.65%67.87B | 20.63%44.79B |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | 3.10%23.88M | -6.40%11.84M | -51.66%2.76M | -50.00%67.53M | -34.26%23.16M | -0.81%12.65M | -91.42%5.7M | -52.96%135.06M | -57.99%35.23M | -66.98%12.76M |
| Cash paid to acquire investments | -34.42%81.93B | -28.94%52.32B | -17.96%26.67B | 65.87%161.93B | 63.04%124.94B | 62.57%73.63B | 2.31%32.51B | -11.05%97.63B | -2.02%76.64B | 3.67%45.29B |
| Impawned loan net increase | 82.68%150.94M | 22.47%89.69M | 240.42%28.58M | 318.30%167.12M | 819.95%82.62M | 247.62%73.23M | 67.10%-20.35M | -35.15%39.95M | 173.69%8.98M | 0.01%-49.61M |
| Net increase in resale business funds (investment) | ---- | --329.62M | --48.62M | ---- | ---- | ---- | ---- | --1.96B | ---- | ---- |
| Cash outflows from investing activities | -34.34%82.11B | -28.44%52.75B | -17.68%26.75B | 62.56%162.17B | 63.08%125.05B | 62.89%73.72B | 2.24%32.49B | -9.40%99.76B | -2.69%76.68B | 3.61%45.26B |
| Net cash flows from investing activities | 155.23%6.8B | 454.01%10.09B | 903.54%14.83B | 76.67%-3.64B | -39.66%-12.3B | -512.46%-2.85B | -3,798.08%-1.85B | -1.50%-15.62B | 15.96%-8.81B | 92.89%-465.4M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | ---- | ---- | ---- | --20M | --20M | --20M | --6.5M | ---- | ---- | ---- |
| -Including: Cash received from capital contributions by minority shareholders of subsidiaries | ---- | ---- | ---- | --20M | --20M | --20M | --6.5M | ---- | ---- | ---- |
| Cash received relating to other financing activities | -46.37%106.31M | -17.94%106.31M | 306.54%106.31M | -54.90%313.56M | 8.65%198.24M | 78.54%129.55M | -55.04%26.15M | 154.53%695.22M | -4.04%182.46M | 7,156.00%72.56M |
| Net increase in repurchase funds (fundraising) | ---- | ---- | ---- | ---- | ---- | -97.05%224.9M | ---- | 142.96%11.76B | 126.73%11.14B | -21.88%7.63B |
| Cash inflows from financing activities | -51.29%106.31M | -71.61%106.31M | 225.60%106.31M | -97.32%333.56M | -98.07%218.24M | -95.14%374.45M | -99.57%32.65M | 54.28%12.46B | 42.17%11.32B | -21.94%7.7B |
| Borrowing repayment | --1.7B | --1.7B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Dividend interest payment | -58.35%466.25M | -71.39%233.3M | 12.80%171M | 6.35%1.41B | 141.71%1.12B | 360.52%815.3M | 103.17%151.6M | 248.44%1.33B | 135.00%463.08M | 33.63%177.04M |
| -Including:Cash payments for dividends or profit to minority shareholders | --10M | --10M | ---- | ---- | ---- | ---- | ---- | --629.29M | ---- | ---- |
| Cash payments relating to other financing activities | ---- | ---- | ---- | 5.32%55.31M | 0.00%1M | 0.00%1M | ---- | -28.85%52.51M | 0.00%1M | 0.00%1M |
| Cash outflows from financing activities | 111.18%8.43B | 1,032.78%9.25B | 8.58%1.83B | 219.27%4.41B | 760.54%3.99B | 358.50%816.3M | 2,160.32%1.69B | 203.48%1.38B | 134.32%464.08M | 33.38%178.04M |
| Net cash flows from financing activities | -120.57%-8.33B | -1,968.72%-9.14B | -4.29%-1.72B | -136.80%-4.08B | -134.78%-3.78B | -105.87%-441.85M | -121.93%-1.65B | 45.37%11.08B | 39.81%10.86B | -22.70%7.52B |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | -143.57%-9.59M | -127.49%-6.76M | 95.71%-237.2K | -71.58%20.47M | -72.87%22.02M | -44.95%24.58M | -109.59%-5.53M | 573.76%72.02M | 2,216.75%81.17M | 644.37%44.66M |
| Net increase in cash and cash equivalents | -2,836.57%-19.81B | -244.75%-17.14B | -227.27%-6.96B | -39.98%1.84B | -152.98%-674.73M | 461.57%11.84B | 65.02%5.47B | 184.81%3.06B | 125.85%1.27B | 152.18%2.11B |
| Add:Begin period cash and cash equivalents | 6.98%28.15B | 6.98%28.15B | 6.98%28.15B | 13.16%26.31B | 13.16%26.31B | 13.16%26.31B | 13.16%26.31B | -13.43%23.25B | -13.43%23.25B | -13.43%23.25B |
| End period cash equivalent | -67.50%8.33B | -71.14%11.01B | -33.33%21.19B | 6.98%28.15B | 4.53%25.63B | 50.44%38.15B | 19.63%31.78B | 13.16%26.31B | 11.83%24.52B | 11.14%25.36B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | China Audit Asia Pacific Accounting Firm (Special General Partnership) | -- | -- | -- | China Audit Asia Pacific Accounting Firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
% Chg
No Data